source
- FDA will miss rare decision deadline for Savara candidate after three-month delaySavara shares dropped 18% on the news, though analysts remain confident in approval, instead pointing to potential “bandwidth issues” at the FDA.BioSpace · 1h ago↗ source
- Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trialLicensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.BioSpace · 2h ago↗ source
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.